Vascular Biogenics Ltd. (NASDAQ:VBLT)’s share price was down 3.4% during trading on Monday . The company traded as low as $4.52 and last traded at $4.55, with a volume of 227,665 shares trading hands. The stock had previously closed at $4.71.

A number of equities analysts have commented on VBLT shares. Roth Capital restated a “buy” rating and issued a $22.00 target price on shares of Vascular Biogenics in a research note on Thursday, June 9th. Chardan Capital reaffirmed a “buy” rating on shares of Vascular Biogenics in a report on Tuesday, June 7th. Piper Jaffray Cos. reaffirmed a “buy” rating and set a $14.00 price target on shares of Vascular Biogenics in a report on Tuesday, June 7th. HC Wainwright started coverage on Vascular Biogenics in a report on Tuesday, June 28th. They set a “buy” rating and a $11.00 price target on the stock. Finally, Zacks Investment Research raised Vascular Biogenics from a “hold” rating to a “buy” rating and set a $4.50 price target on the stock in a report on Thursday, August 18th. Two investment analysts have rated the stock with a hold rating and five have issued a buy rating to the company. The stock currently has a consensus rating of “Buy” and an average target price of $13.67.

The company has a 50 day moving average of $4.13 and a 200 day moving average of $3.82. The stock’s market cap is $107.15 million.

Vascular Biogenics (NASDAQ:VBLT) last announced its quarterly earnings data on Monday, August 15th. The biopharmaceutical company reported ($0.14) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.23) by $0.09. Equities analysts expect that Vascular Biogenics Ltd. will post ($0.64) EPS for the current year.

A number of hedge funds have recently bought and sold shares of VBLT. Migdal Insurance & Financial Holdings Ltd. acquired a new stake in Vascular Biogenics during the second quarter worth $1,844,000. Turner Investments L.P. acquired a new stake in Vascular Biogenics during the second quarter worth $1,007,000. First Eagle Investment Management LLC boosted its stake in Vascular Biogenics by 371.1% in the second quarter. First Eagle Investment Management LLC now owns 923,239 shares of the biopharmaceutical company’s stock worth $4,256,000 after buying an additional 727,273 shares during the last quarter. Macquarie Group Ltd. acquired a new stake in Vascular Biogenics during the second quarter worth $1,521,000. Finally, Menta Capital LLC boosted its stake in Vascular Biogenics by 4.1% in the second quarter. Menta Capital LLC now owns 33,200 shares of the biopharmaceutical company’s stock worth $153,000 after buying an additional 1,300 shares during the last quarter. 14.46% of the stock is currently owned by institutional investors and hedge funds.

About Vascular Biogenics

Vascular Biogenics Ltd. is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of treatments for cancer. The Company’s program is based on its Vascular Targeting System (VTS) platform technology, which utilizes genetically targeted therapy to destroy newly formed, or angiogenic, blood vessels.

5 Day Chart for NASDAQ:VBLT

Receive News & Ratings for Vascular Biogenics Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vascular Biogenics Ltd. and related companies with Analyst Ratings Network's FREE daily email newsletter.